Onconetix and Ocuvex terminate merger agreement mutually

Onconetix Inc. (NASDAQ: ONCO) and Ocuvex Therapeutics Inc. announced the mutual termination of their merger agreement originally signed July 16, 2025.

The biotechnology companies said they determined pursuing independent paths serves their respective stakeholders better after careful consideration and discussions.

Ocuvex CEO Anthony Amato said the termination does not affect the company's momentum or patient commitment. He announced Ocuvex received its New Jersey state pharmaceutical license and will launch its Omlonti product in coming weeks.

"The decision to mutually terminate the merger agreement does not impact Ocuvex's momentum or our commitment to patients," Amato stated.

Andrew Oakley, Onconetix Chairman, expressed confidence in Ocuvex's prospects despite the separation. "Despite our decision to part ways, we are confident that Omlonti will deliver value for patients and the ophthalmic community upon launch and future growth," he said.

Onconetix focuses on men's health and oncology solutions and owns Proclarix, a prostate cancer diagnostic test approved for sale in the European Union. Ocuvex specializes in ophthalmic treatments and product development.

Both companies expressed appreciation for the collaborative approach during merger discussions. The information comes from a joint press release issued by the companies.

You May Also Be Interested In

• Boxabl completes SPAC merger, begins trading on Nasdaq at $3.5B value
• DBV Technologies refreshes ATM program with $150M ADS offering
• TXNM Energy and Blackstone extend merger deadline to May 2027